Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by lonc17on Mar 23, 2023 7:27pm
174 Views
Post# 35357617

RE:RE:SP

RE:RE:SPList of failed trials (partial list, going from memory):

Prostate
Glioblastoma
Melanoma
Head and Neck
Sarcoma
Lung Cancer
Bladder
Ovarian

Is that enough?  I could probably find a few more, like the children's solid tumour trial that was never once mentioned by ONC after failure. 

Tough to keep track of, I know, because ONC changed the name of their product from Reolysin to Pelareoreop. They did this to help bury the past and start afresh as a "Breast Cancer" company, which I always thought would have read better as "Breast Cancer Treatment" company. 

So Reolysin was rebranded as Pelareorep and now you can say Pelareorep has no failed trials. Well done!  Excellent job from the PR department. 

Go ONC!
<< Previous
Bullboard Posts
Next >>